299 related articles for article (PubMed ID: 33250513)
21. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
22. Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells.
Che F; Ye X; Wang Y; Ma S; Wang X
Eur J Pharmacol; 2021 Jan; 891():173752. PubMed ID: 33253679
[TBL] [Abstract][Full Text] [Related]
23. CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.
Thangavadivel S; Zelle-Rieser C; Olivier A; Postert B; Untergasser G; Kern J; Brunner A; Gunsilius E; Biedermann R; Hajek R; Pour L; Willenbacher W; Greil R; Jöhrer K
Oncotarget; 2016 Nov; 7(48):78605-78618. PubMed ID: 27732933
[TBL] [Abstract][Full Text] [Related]
24. RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma.
Gu C; Lu T; Wang W; Shao M; Wei R; Guo M; Li R; Qiao L; Hu Y; Zhan F; Seckinger A; Hose D; Yang Y
Leukemia; 2021 Jun; 35(6):1803-1807. PubMed ID: 32901100
[No Abstract] [Full Text] [Related]
25. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
[TBL] [Abstract][Full Text] [Related]
26. [Research Progress on Mechanism of Bortezomib Resistance in Multiple Myeloma].
Wang YR; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1584-1587. PubMed ID: 37846721
[TBL] [Abstract][Full Text] [Related]
27. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance.
Dolloff NG
Adv Cancer Res; 2015; 127():191-226. PubMed ID: 26093901
[TBL] [Abstract][Full Text] [Related]
28. A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment.
Chroma K; Skrott Z; Gursky J; Bacovsky J; Moudry P; Buchtova T; Mistrik M; Bartek J
Cell Death Dis; 2022 Mar; 13(3):203. PubMed ID: 35246527
[TBL] [Abstract][Full Text] [Related]
29. Pluronic block copolymers enhance the anti-myeloma activity of proteasome inhibitors.
Hu H; Petrosyan A; Osna NA; Liu T; Olou AA; Alakhova DY; Singh PK; Kabanov AV; Faber EA; Bronich TK
J Control Release; 2019 Jul; 306():149-164. PubMed ID: 31121280
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
[TBL] [Abstract][Full Text] [Related]
31. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma.
Franqui-Machin R; Hao M; Bai H; Gu Z; Zhan X; Habelhah H; Jethava Y; Qiu L; Frech I; Tricot G; Zhan F
J Clin Invest; 2018 Jul; 128(7):2877-2893. PubMed ID: 29863498
[TBL] [Abstract][Full Text] [Related]
32. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
[TBL] [Abstract][Full Text] [Related]
33. Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.
Zhou Y; Liu X; Xue J; Liu L; Liang T; Li W; Yang X; Hou X; Fang H
J Med Chem; 2020 May; 63(9):4701-4715. PubMed ID: 32267687
[TBL] [Abstract][Full Text] [Related]
34. DUT enhances drug resistance to proteasome inhibitors via promoting mitochondrial function in multiple myeloma.
Wang Y; Gao S; Chen L; Liu S; Ma J; Cao Z; Li Q
Carcinogenesis; 2022 Dec; 43(11):1030-1038. PubMed ID: 36426924
[TBL] [Abstract][Full Text] [Related]
35. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
Malek E; Driscoll JJ
Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
[TBL] [Abstract][Full Text] [Related]
36. Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy.
Beyar-Katz O; Magidey K; Reiner-Benaim A; Barak N; Avivi I; Cohen Y; Timaner M; Avraham S; Hayun M; Lavi N; Bersudsky M; Voronov E; Apte RN; Shaked Y
Mol Cancer Res; 2019 Nov; 17(11):2331-2340. PubMed ID: 31409628
[TBL] [Abstract][Full Text] [Related]
37. Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.
Thompson RM; Dytfeld D; Reyes L; Robinson RM; Smith B; Manevich Y; Jakubowiak A; Komarnicki M; Przybylowicz-Chalecka A; Szczepaniak T; Mitra AK; Van Ness BG; Luczak M; Dolloff NG
Oncotarget; 2017 May; 8(22):35863-35876. PubMed ID: 28415782
[TBL] [Abstract][Full Text] [Related]
38. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
Bono C; Karlin L; Harel S; Mouly E; Labaume S; Galicier L; Apcher S; Sauvageon H; Fermand JP; Bories JC; Arnulf B
Haematologica; 2012 Jul; 97(7):1101-9. PubMed ID: 22271897
[TBL] [Abstract][Full Text] [Related]
39. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
40. VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification.
Pundir S; Vu HY; Solomon VR; McClure R; Lee H
Cancer Res; 2015 Oct; 75(19):4164-75. PubMed ID: 26238784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]